公开(公告)号：US20200323859A1

公开(公告)日：2020-10-15

申请号：US16863631

申请日：2020-04-30

Applicant: Novartis AG

Inventor： Ho Man CHAN ,  Xiang-Ju Justin GU ,  Ying HUANG ,  Ling LI ,  Yuan MI ,  Wei QI ,  Martin SENDZIK ,  Yongfeng SUN ,  Long WANG ,  Zhengtian YU ,  Hailong ZHANG ,  Ji Yue (Jeff) ZHANG ,  Man ZHANG ,  Qiong ZHANG ,  Kehao ZHAO

IPC: A61K31/519 ,  C07D487/04 ,  A61K45/06 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/551

Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.

公开(公告)号：US20250092036A1

公开(公告)日：2025-03-20

申请号：US18800559

申请日：2024-08-12

Applicant: Novartis AG

Inventor： Erich W. BAUM ,  Thomas A. DINEEN, JR. ,  Jonathan Edward HEMPEL ,  Matthew James HESSE ,  Robert KOENIG ,  Matthew James LAMARCHE ,  Jay Francis LARROW ,  Ruowei MO ,  Henrik MOEBITZ ,  Rukundo NTAGANDA ,  Keith Bruce PFISTER ,  Martin SENDZIK ,  Colin Keith SKEPPER ,  Joseph WZOREK, JR. ,  Frédéric ZECRI

IPC: C07D471/04 ,  A61K31/454 ,  A61K31/4545 ,  A61P35/00 ,  C07D401/06 ,  C07D405/14 ,  C07D491/052

Abstract: The invention relates to compounds which modulate the activity of ERK. The present invention also relates to processes for the preparation of said compounds, pharmaceutical compositions comprising said compounds, and use of said compounds in the treatment of conditions, diseases and disorders mediated by ERK.

公开(公告)号：US20210300919A1

公开(公告)日：2021-09-30

申请号：US17130374

申请日：2020-12-22

Applicant: Novartis AG

Inventor： Zhuoliang CHEN ,  Jorge Garcia FORTANET ,  Rajesh KARKI ,  Matthew J. LAMARCHE ,  Dyuti MAJUMDAR ,  Lawrence Blas PEREZ ,  Martin SENDZIK ,  Troy Douglas SMITH ,  Fan YANG ,  Bing YU

IPC: C07D471/04 ,  C07D513/04 ,  C07D495/04 ,  C07D487/04 ,  C07D401/14 ,  C07D519/00 ,  C07D455/02 ,  C07D403/14 ,  A61P35/00

Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, R1, R2 and R3 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

公开(公告)号：US20190142837A1

公开(公告)日：2019-05-16

申请号：US16246380

申请日：2019-01-11

Applicant: Novartis AG

Inventor： Ho Man CHAN ,  Xiang-Ju Justin GU ,  Ying HUANG ,  Ling LI ,  Yuan MI ,  Wei QI ,  Martin SENDZIK ,  Yongfeng SUN ,  Long WANG ,  Zhengtian YU ,  Hailong ZHANG ,  Ji Yue (Jeff) ZHANG ,  Man ZHANG ,  Qiong ZHANG ,  Kehao ZHAO

IPC: A61K31/519 ,  A61K45/06 ,  A61K31/551 ,  C07D487/04 ,  A61K31/5377 ,  A61K31/541

Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.